Company profile
DiaMedica Therapeutics Inc.
NASDAQ:DMACBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Rinvecalinase Alfa | phase2 | — | 4 | completed, withdrawn |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01845064 | phase1_2 | completed | 2013-04-01 | 2014-09-01 | DiaMedica Therapeutics Inc | A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes Patients |
| NCT02868996 | phase1 | completed | 2016-09-01 | 2017-03-01 | DiaMedica Therapeutics Inc | An Open Label, Phase 1b, Ascending Dose Study of DM199 |
| NCT06875141 | — | withdrawn | 2025-05-01 | 2025-05-01 | DiaMedica Therapeutics Inc | DM199 for Pregnancy Complications |
| NCT03290560 | phase2 | completed | 2018-01-19 | 2020-01-23 | DiaMedica Therapeutics Inc | Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke |
| NCT04123613 | phase2 | completed | 2019-12-17 | 2022-03-16 | DiaMedica Therapeutics Inc | Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX) |
FDA applications (0)
No records yet.